Back to mobile site

Intellipharmaceutics (IPCI) Not Required to Conduct Rexista Oxycodone XR Phase 3 if Oxycontin Bioequivalence Demonstrated

May 21, 2015 8:04 AM EDT Send to a Friend
Intellipharmaceutics International (NASDAQ: IPCI) announced that the United States Food and Drug Administration ("FDA") provided the Company with notification regarding ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login